

Resource Summary Report

Generated by [Kravitz](#) on Sep 10, 2026

NIH AIDS Reagent Program

RRID:SCR_023191

Type: Tool

Proper Citation

NIH AIDS Reagent Program (RRID:SCR_023191)

Resource Information

URL: <https://www.hivreagentprogram.org/>

Proper Citation: NIH AIDS Reagent Program (RRID:SCR_023191)

Description: NIH HIV Reagent Program has been managed under contract by American Type Culture Collection (ATCC) since 2020. ATCC shall maintain the NIH HIV Reagent Program through identification, acquisition, production, receipt, storage, maintenance, distribution and disposal of biological and chemical research organisms and materials for HIV and other infectious diseases for use in basic and translational research.

Abbreviations: NIH-ARP

Resource Type: biobank, material storage repository, service resource, storage service resource

Resource Name: NIH AIDS Reagent Program

Resource ID: SCR_023191

Record Creation Time: 20230126T050201+0000

Record Last Update: 20260905T133432+0000

Ratings and Alerts

No rating or validation information has been found for NIH AIDS Reagent Program .

No alerts have been found for NIH AIDS Reagent Program .

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1976 mentions in open access literature.

Listed below are recent publications. The full list is available at [Kravitz](#) .

Fu Y, et al. (2026) Structural and functional modifications of neuronal lipid rafts: implications for HIV-associated neurological disorders. *Journal of neuroinflammation*, 23(1).

Mesner D, et al. (2026) HIV-1 signalling remodels nuclear pores to licence infection. *Nature*, 654(8120), 1044.

van Paassen PM, et al. (2026) HIV-specific CD8+ T-cell proliferative response 24 weeks after early antiretroviral therapy initiation is associated with the subsequent reduction in the viral reservoir. *eLife*, 14.

D??az-Salinas MA, et al. (2026) Conformational dynamics of the HIV-1 envelope glycoprotein from CRF01_AE is associated with susceptibility to antibody-dependent cellular cytotoxicity. *Journal of virology*, 100(1), e0166725.

Panda K, et al. (2026) HIV disrupts the lung molecular clock, leading to lung inflammation and features of emphysema. *Communications biology*, 9(1), 11.

Mishra N, et al. (2026) Germline-targeting HIV immunogen induces cross-neutralizing antibodies in outbred macaques. *Immunity*, 59(4), 1140.

Maroney KJ, et al. (2026) CD8+ T cells cross-restricted by HLA-B*57 and HLA-E*01 recognize HIV Gag with different functional profiles. *JCI insight*, 11(3).

Kuhlmann AS, et al. (2026) Comparative In Vitro Evaluation of Anti-HIV Immunotoxin, Antibody-Drug Conjugate, and Radioimmunoconjugate Targeted by the Same Antibody. *Antibodies (Basel, Switzerland)*, 15(1).

Jansen J, et al. (2026) Blocking Host Factors IAP and DDX3 Activates HIV-1 Transcription and Increases Apoptosis Sensitivity of HIV-1 Infected Cells. *Pathogens (Basel, Switzerland)*, 15(6).

Hu Q, et al. (2025) Cell type differences in human cytomegalovirus transcription and epigenetic regulation with insights into major immediate-early enhancer-promoter control. *PLoS pathogens*, 21(8), e1013374.

Bhargavan B, et al. (2025) Glycogen synthase kinase-3 activation and dysregulation of amyloid transport receptors expression and shedding in HIV-induced Alzheimer's disease-like pathology: modulatory effects of CCR5 antagonists. *Acta neuropathologica communications*, 14(1), 16.

Hansen D, et al. (2025) Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavir. *mBio*, 16(5), e0018725.

Katte RH, et al. (2025) Inter-protomer opening cooperativity of envelope trimers positively correlates with HIV-1 entry stoichiometry. *mBio*, 16(4), e0275424.

Kumar S, et al. (2025) The Design and Immunogenicity of an HIV-1 Clade C Pediatric Envelope Glycoprotein Stabilized by Multiple Platforms. *Vaccines*, 13(2).

Khuzwayo SS, et al. (2025) The synthesis and investigation of novel 3-benzoylbenzofurans and pyrazole derivatives for anti-HIV activity. *RSC medicinal chemistry*, 16(5), 2142.

Graur A, et al. (2025) HIV-1 gp120 Interactions with Nicotine Modulate Mitochondrial Network Properties and Amyloid Release in Microglia. *Neurochemical research*, 50(2), 103.

Sajadi MM, et al. (2025) A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV. *Structure (London, England : 1993)*, 33(7), 1150.

Silvestre C, et al. (2025) NK Count and Natural Cytotoxicity in Immune Nonresponders Versus Responders Living With HIV. *Journal of medical virology*, 97(2), e70170.

Molina Molina E, et al. (2025) Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m6A protein synthesis routes. *Nature communications*, 16(1), 1087.

Tan CD, et al. (2025) Rapid Multi-Well Evaluation of Assorted Materials for Hydrogel-Assisted Giant Unilamellar Vesicle Production: Empowering Bottom-Up Synthetic Biology. *Gels (Basel, Switzerland)*, 11(1).